{"id":10303,"date":"2006-09-15T01:58:59","date_gmt":"2006-09-14T23:58:59","guid":{"rendered":"http:\/\/www.fedaiisf.it\/bms-nuova-era\/"},"modified":"2006-09-15T01:58:59","modified_gmt":"2006-09-14T23:58:59","slug":"bms-nuova-era","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/bms-nuova-era\/","title":{"rendered":"BMS new era"},"content":{"rendered":"<div class=\"Style_3\">The &#039;Plavix case*&#039; has revolutionized the management of Bristol-Myers Squibb. After the arrival on the market, ahead of expectations and attempts to &#039;blow it up&#039;, of the generic of one of Bms&#039; best-selling champions, Plavix*, executive director Peter Dolan and general counsel Richard Willard left their positions, not quite spontaneously. James Cornelius has already been appointed executive director ad interim: a move that took place quickly to reassure investors, in a delicate moment for BMS, which is starting to focus on future growth profiles. From From Adnkronos 09-14-06<\/div>","protected":false},"excerpt":{"rendered":"<p>Il &#8216;caso Plavix*&#8217; ha rivoluzionato i vertici di Bristol-Myers Squibb. Dopo l&#8217;arrivo sul mercato, in anticipo rispetto alle previsioni e ai tentativi di &#8216;farlo saltare&#8217;, del generico di uno dei campioni di vendite di Bms, il Plavix* appunto, il direttore esecutivo Peter Dolan e il consigliere generale Richard Willard hanno lasciato, non proprio spontaneamente, i &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-10303","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/10303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=10303"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/10303\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=10303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=10303"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=10303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}